Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea in PED Secondary to Neovascular AMD
NCT02142296Phase 4Completed
- Start
- May 2014
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD). Started May 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02142296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142296.